

RECEIVED  
CENTRAL FAX CENTER

FEB 06 2008

**FAX TRANSMISSION****DATE:** February 6, 2008**PTO IDENTIFIER:** Application Number 10/565,828-Conf. #7933  
Patent Number**Inventor:** Hidetsugu Takagaki et al.**MESSAGE TO:** US Patent and Trademark Office**FAX NUMBER:** (571) 273-8300**FROM:** EDWARDS ANGELL PALMER & DODGE LLP  
James E. Armstrong, IV**PHONE:** (202) 478-7370**Attorney Dkt. #:** 80657(47762)**PAGES (Including Cover Sheet):** 4**CONTENTS:** Statement By Assignee to Establish Ownership (37 CFR 3.73(b)) (1 page)  
Power of Attorney to Prosecute Application before the USPTO (1 page)  
Certificate of Transmission (1 page)

If your receipt of this transmission is in error, please notify this firm immediately by collect call to sender at (202) 478-7370 and send the original transmission to us by return mail at the address below.

This transmission is intended for the sole use of the individual and entity to whom it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. You are hereby notified that any dissemination, distribution or duplication of this transmission by someone other than the intended addressee or its designated agent is strictly prohibited.

**EDWARDS ANGELL PALMER & DODGE LLP**  
1875 Eye Street, NW, Washington, DC 20006  
**Telephone:** (202) 478-7370 **Facsimile:** (202) 478-7380

FEB 06 2008

PTO/SB/97 (09-04)

Approved for use through 07/31/2008. OMB 0851-0031

U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application No. (if known): 10/565,828

Attorney Docket No.: 80657(47762)

**Certificate of Transmission under 37 CFR 1.8**

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office.

on February 6, 2008  
Date

  
Signature

James E. Armstrong, IV

Typed or printed name of person signing Certificate

42,266

Registration Number, if applicable

(202) 478-7370

Telephone Number

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

Statement By Assignee to Establish Ownership (37 CFR 3.73(b)) (1 page)

Power of Attorney to Prosecute Application before the USPTO (1 page)

FEB 06 2008

PTO/SB/96 (10-07)

Approved for use through 10/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**STATEMENT UNDER 37 CFR 3.73(b)**Applicant/Patent Owner: Activus Pharma Co., Ltd.Application No./Patent No.: 10/565,828 Filed/Issue Date: January 25, 2006THERAPEUTIC AGENT FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND  
METHOD FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE USING THEEntitled: SAMEActivus Pharma Co., Ltd., a Corporation  
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.  
(The extent (by percentage) of its ownership interest is \_\_\_\_\_ %)

in the patent application/patent identified above by virtue of either:

- A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

OR

- B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: Takagaki, Hidetsugu, et al. To: Dainippon Ink and Chemicals, Inc.  
The document was recorded in the United States Patent and Trademark Office at  
Reel 017510, Frame 0617, or for which a copy thereof is attached.
2. From: Dainippon Ink and Chemicals, Inc. To: Activus Pharma Co., Ltd.  
The document was recorded in the United States Patent and Trademark Office at  
Reel 019861, Frame 0128, or for which a copy thereof is attached.
3. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at  
Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

- ☒ As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

James E. Armstrong IV  
SignatureFebruary 6, 2008  
DateJames E. Armstrong IV  
Printed or Typed Name202 478 7375  
Telephone NumberAuthorized Signer for Assignee  
Title

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted by facsimile to the Patent and Trademark Office, facsimile no. (571) 273-8300, on the date shown below.

Dated: February 6, 2008

Signature: James E. Armstrong IV (James E. Armstrong, IV)

FEB 06 2008

OSP-19463

PTO/SB/80 (01-06)  
Approved for use through 12/31/2008. OMB 0851-0035  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**POWER OF ATTORNEY TO PROSECUTE APPLICATIONS BEFORE THE USPTO**

I hereby revoke all previous powers of attorney given in the application identified in the attached statement under 37 CFR 3.73(b).

I hereby appoint:



Practitioners associated with the Customer Number:

21874

OR



Practitioner(s) named below (if more than ten patent practitioners are to be named, then a customer number must be used):

Name	Registration Number	Name	Registration Number

as attorney(s) or agent(s) to represent the undersigned before the United States Patent and Trademark Office (USPTO) in connection with any and all patent applications assigned only to the undersigned according to the USPTO assignment records or assignment documents attached to this form in accordance with 37 CFR 3.73(b).

Please change the correspondence address for the application identified in the attached statement under 37 CFR 3.73(b) to:



The address associated with Customer Number:

21874

OR



Firm or Individual Name

James E. Armstrong, IV  
EDWARDS ANGELL PALMER & DODGE LLP

Address P.O. Box 55874

City Boston

State

MA

Zip

02205

Country US

Telephone

(202) 478-7370

Email

jarmstrong@eapdlaw.com


Assignee Name and Address:

Activus Pharma Co., Ltd.  
526-6, Roppogaoka  
Yotsukaido-shi, Chiba 284-0008, Japan

A copy of this form, together with a statement under 37 CFR 3.73(b) (Form PTO/SB/96 or equivalent) is required to be filed in each application in which this form is used. The statement under 37 CFR 3.73(b) may be completed by one of the practitioners appointed in this form if the appointed practitioner is authorized to act on behalf of the assignee, and must identify the application in which this Power of Attorney is to be filed.

**SIGNATURE of Assignee of Record**

The individual whose signature and title is supplied below is authorized to act on behalf of the assignee


Signature		Date	Jan 23, 2008
Name	Yasuo AOKI	Telephone	(43-301-5050)
Title	President		

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted by facsimile to the Patent and Trademark Office, facsimile no. (571) 273-8300, on the date shown below

Dated:

2-6-08

Signature:



James E. Armstrong, IV

DC\_Activus Pharma Co., Ltd. POA.doc